🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ray Dalio’s RYTM Holdings & Trades

First Buy
Q3 2026
Duration Held
1 Quarters
Largest Add
Q3 2026
+95,074 Shares
Current Position
95,074 Shares
$9.05 M Value

Ray Dalio's RYTM Position Overview

Ray Dalio (via Bridgewater Associates, Lp) currently holds 95,074 shares of Rhythm Pharmaceuticals, Inc. (RYTM) worth $9.05 M, representing 0.04% of the portfolio. First purchased in 2026-Q3, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Ray Dalio has initiated a new position in RYTM, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Ray Dalio's Rhythm Pharmaceuticals (RYTM) Holding Value Over Time

Track share changes against reported price movement

Quarterly Rhythm Pharmaceuticals (RYTM) Trades by Ray Dalio

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2026 +95,074 New Buy 95,074 $95.22

Ray Dalio's Rhythm Pharmaceuticals Investment FAQs

Ray Dalio first purchased Rhythm Pharmaceuticals, Inc. (RYTM) in Q3 2026, acquiring 95,074 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio has held Rhythm Pharmaceuticals, Inc. (RYTM) for 1 quarters since Q3 2026.

Ray Dalio's largest addition to Rhythm Pharmaceuticals, Inc. (RYTM) was in Q3 2026, adding 95,074 shares worth $9.05 M.

According to the latest 13F filing for Q3 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 95,074 shares of Rhythm Pharmaceuticals, Inc. (RYTM), valued at approximately $9.05 M.

As of the Q3 2026 filing, Rhythm Pharmaceuticals, Inc. (RYTM) represents approximately 0.04% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.

Ray Dalio's peak holding in Rhythm Pharmaceuticals, Inc. (RYTM) was 95,074 shares, as reported at the end of Q3 2026.